A First-in-Human (FIH), Randomized, Dose-Escalation, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SPC4955 Administered to Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 25 Apr 2014
At a glance
- Drugs SPC 4955 (Primary)
- Indications Hypercholesterolaemia
- Focus Adverse reactions
- Sponsors Santaris Pharma
- 21 Nov 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 21 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.